+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Cerebrospinal Fluid Immunoreactive Somatostatin Concentrations in Patients with Cushing’s Disease and Major Depression: Relationship to Indices of Corticotropin-Releasing Hormone and Cortisol Secretion

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To further explore the differential effects of peripherally and centrally derived hypercortisolism on neurohormonal systems implicated in the pathophysiology of mood and cognitive disturbances, we examined the cerebrospinal fluid (CSF) concentrations of immunoreactive somatostatin (IR-SRIF) in patients with Cushing’s disease and major depression and the relationship of these levels to CSF immunoreactive corticotropin-releasing hormone (CRH) concentrations and urinary free cortisol excretion. In particular, since CSF SRIF levels consistently have been shown to be reduced in depression, we wished to assess whether decreased centrally directed SRIF was more likely a primary or a secondary factor in the hypercortisolism of major depression. CSF SRIF levels were significantly reduced in 11 patients with documented Cushing’s disease and in 1 patient with ectopic adrenocorticotropic hormone secretion as compared with both 41 healthy volunteers (19.4 ± 2.9 vs. 37.4 ± 1.5 pmol/l; p < 0.01) and 28 patients with major depression (30.2 ± 2.4 pmol/l; p < 0.05), whose CSF SRIF levels were also significantly reduced as compared with controls (p < 0.05). CSF SRIF levels in the Cushing’s disease patients correlated positively with CSF CRH (r = 0.64; p < 0.025), suggesting that either the sustained hypercortisolism in these patients and/or its suppression of central CRH secretion contributed to the reduction in SRIF. A more modest but significant correlation between CSF SRIF and CSF CRH was observed in the healthy volunteers (r = 0.37; d.f. = 37; p < 0.02); in the depressed patients, no linear relationship, but rather an inverted U-shaped relationship was found which significantly fit by a quadratic function (r<sup>2</sup> = 0.90; d.f. = 22; p < 0.001). In the depressed patients, the CSF SRIF levels also showed an inverted quadratic relationship with urinary free cortisol excretion (r<sup>2</sup> = 0.87; d.f. = 16; p < 0.001). These findings, together with those from recent preclinical and human volunteer studies, suggest that CRH is a positive modulator of central SRIF release under physiological conditions, while glucocorticoid excess tends to suppress SRIF. These data are of interest in the light of evidence suggesting an involvement of SRIF in functions such as mood regulation, learning, and memory which are disturbed in both Cushing’s disease and major depression.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 57
          : 1
          : 79-88
          aClinical Neuroendocrinology Branch, bBiological Psychiatry Branch, cClinical Neurosciences Branch, National Institute of Mental Health, dDevelopmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda, Md., USA
          126345 Neuroendocrinology 1993;57:79–88
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Original Paper


          Comment on this article